Summary:
- This article discusses a Cochrane review that examined the effectiveness of anti-amyloid monoclonal antibodies in treating Alzheimer's disease.
- The review found that these antibodies, which target the amyloid protein believed to be a key driver of Alzheimer's, did not significantly improve cognitive or functional outcomes for patients with mild to moderate Alzheimer's.
- The findings highlight the need for continued research to better understand the underlying causes of Alzheimer's and develop more effective treatments for this devastating disease.